Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 5/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100381 | 0.94 | PTGES (0.52) | PTGESALOX5TRPM8MEN1KMT2A | |
| SCHEMBL1099414 | 0.92 | PTGES (0.58) | PTGESALOX5TRPM8KMT2ATAS2R14 | |
| SCHEMBL1099039 | 0.92 | PTGES (0.55) | PTGESALOX5TRPM8TAS2R14 | |
| SCHEMBL1100098 | 0.91 | PTGES (0.59) | PTGESALOX5TRPM8PSEN1PSEN2 | |
| SCHEMBL1100771 | 0.84 | LMNA (0.41) | PTGESALOX5TRPM8MEN1KMT2A | |
| SCHEMBL1100475 | 0.84 | TRPM8 (0.47) | PTGESALOX5TRPM8MEN1KMT2A | |
| SCHEMBL1098592 | 0.82 | TRPM8 (0.49) | TRPM8 | |
| SCHEMBL1099966 | 0.82 | TRPM8 (0.60) | PTGESALOX5TRPM8 | |
| SCHEMBL1098424 | 0.82 | PTGES (0.52) | PTGESALOX5TRPM8MEN1KMT2A | |
| SCHEMBL1100154 | 0.81 | TRPM8 (0.42) | PTGESALOX5TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809327-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-19 | — | — | US | disclosed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | PTGES 309/4885ALOX5 2892/4885TRPM8 1/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | PTGES 309/4885ALOX5 2892/4885TRPM8 1/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | PTGES 309/4885ALOX5 2892/4885TRPM8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.